{"id":"NCT02530294","sponsor":"Journey Medical Corporation","briefTitle":"Study of Glycopyrronium in Subjects With Axillary Hyperhidrosis","officialTitle":"A Phase 3, Randomized, Double-blind, Vehicle-controlled Efficacy and Safety Study of Glycopyrronium in Subjects With Axillary Hyperhidrosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-08","primaryCompletion":"2016-04","completion":"2016-04","firstPosted":"2015-08-21","resultsPosted":"2018-08-14","lastUpdate":"2021-08-25"},"enrollment":353,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hyperhidrosis"],"interventions":[{"type":"DRUG","name":"glycopyrronium Topical Wipes","otherNames":["DRM04"]},{"type":"OTHER","name":"Vehicle","otherNames":[]}],"arms":[{"label":"glycopyrronium","type":"EXPERIMENTAL"},{"label":"Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"The study is a randomized, double-blind, vehicle controlled, parallel group study, designed to assess the efficacy and safety of glycopyrronium topical wipes, once daily, compared to vehicle in subjects with axillary hyperhidrosis.","primaryOutcome":{"measure":"Percentage of Subjects Who Have a â‰¥4-point Improvement in the Weekly Mean Score of Axillary Sweating Daily Diary (ASDD) Item #2 From Baseline at Week 4","timeFrame":"From Baseline to Week 4","effectByArm":[{"arm":"Glycopyrronium","deltaMin":66.1,"sd":null},{"arm":"Vehicle","deltaMin":26.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.001"}]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":14},"locations":{"siteCount":20,"countries":["United States"]},"refs":{"pmids":["32147881","31111409","30378087"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":232},"commonTop":["Dry Mouth","Application site pain","Oropharyngeal pain","Mydriasis","Headache"]}}